Stock MIRAGEN THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Miragen Therapeutics Inc Nasdaq

Equities

US8266402036

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Miragen Therapeutics Inc
Jun. 11 Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Jun. 11 Sector Update: Health Care MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT
Sector Update: Health Care
MT
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins
MT
Wolfe Research Initiates Coverage on Viridian Therapeutics With Outperform Rating, $29 Price Target
MT
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket
MT
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
BU
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-To-Severe Thyroid Eye Disease
CI
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Goldman Sachs Initiates Coverage on Viridian Therapeutics With Buy Rating, $23 Price Target
MT
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
BU
Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
AQ
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
BU
Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating
MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy
MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. Stock
  5. News Miragen Therapeutics Inc